@AshwinShindeMD @pipcosper Agree it's rare in the monoclonal antibody space, but not unheard of as with KEYNOTE-006 -- pembro (Merck) vs. ipi (BMS). Definitely room for improvement with anti-PD1/PD-L1 agents. https://t.co/LotJma1Wy6 https://t.co/1WCbrmagZQ
Yes. @Jia_Luo did this work and found the majority of head to head monoclonal Ab cancer trials favor the sponsor; what was also concerning is how few there are compared with what could be.
Whenever you see a H2H study, there is no need to look further. Sponsor wins all the time 100%, We hope @VPrasadMDMPH agrees; https://t.co/jmBWPNNRMS
RT @AmadeoWals: A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical tr…